Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina
Author:
- 27 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (18) , 2485-2495
Abstract
Background and objectives: Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina. Methods: One-year mortality was assessed in patients stratified according to region of residence, and factors associated with death were evaluated in multivariable Cox models. Results: At TB diagnosis, patients in Eastern Europe had less advanced immunodeficiency, whereas a greater proportion had a history of intravenous drug use, coinfection with hepatitis C, disseminated TB, and infection with drug-resistant TB (P < 0.0001). In Eastern Europe, fewer patients initiated TB treatment containing at least rifamycin, isoniazid, and pyrazinamide or combination antiretroviral therapy (P < 0.0001). Mortality at 1 year was 27% in Eastern Europe, compared with 7, 9 and 11% in Central/Northern Europe, Southern Europe, and Argentina, respectively (P < 0.0001). In a multivariable model, the adjusted relative hazard of death was significantly lower in each of the other regions compared with Eastern Europe: 0.34 (95% confidence interval 0.17–0.65), 0.28 (0.14–0.57), 0.34 (0.15–0.77) in Argentina, Southern Europe and Central/Northern Europe, respectively. Factors significantly associated with increased mortality were CD4 cell count less than 200 cells/μl [2.31 (1.56–3.45)], prior AIDS [1.74 (1.22–2.47)], disseminated TB [2.00 (1.38–2.85)], initiation of TB treatment not including rifamycin, isoniazid and pyrazinamide [1.68 (1.20–2.36)], and rifamycin resistance [2.10 (1.29–3.41)]. Adjusting for these known confounders did not explain the increased mortality seen in Eastern Europe. Conclusion: The poor outcome of patients with HIV/TB in Eastern Europe deserves further study and urgent public health attention.Keywords
This publication has 15 references indexed in Scilit:
- Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysisAnnals of Internal Medicine, 2008
- Tuberculosis–HIV co‐infection: policy and epidemiology in 25 countries in the WHO European regionHIV Medicine, 2008
- Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North AmericaClinical Infectious Diseases, 2005
- Incidence of Tuberculosis during Highly Active Antiretroviral Therapy in High-Income and Low-Income CountriesClinical Infectious Diseases, 2005
- BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005HIV Medicine, 2005
- Outcome of HIV‐Associated Tuberculosis in the Era of Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2004
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infectionAIDS, 2000
- Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected Patients after the Introduction of Highly Active Antiretroviral TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patientsEuropean Respiratory Journal, 1998